Anacor, GSK revise R&D pact on boron-containing anti-infective drug candidates
This article was originally published in Scrip
Executive Summary
Anacor Pharmaceuticals has received a $5 million upfront payment for entering into an amended – and expanded – R&D collaboration with GlaxoSmithKline.